OrbiMed Advisors THC Position
ExitedOrbiMed Advisors exited their position in TENET HEALTHCARE CORP (THC) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
2 other tracked funds also hold THC.
About TENET HEALTHCARE CORP
Tenet Healthcare Corporation operates as a diversified healthcare services company. The company operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; quaternary care services in heart and kidney transplants; and limb-salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging, and telemedicine access services. In addition, it operates ambulatory surgery and urgent care centers, imaging centers, surgical hospitals, off-campus emergency departments, and micro-hospitals; and offers healthcare business process services in the areas of hospital and physician revenue cycle management, patient communications and engagement support, and value-based care solutions to hospitals, health systems, physician practices, employers, and other customers. As of February 09, 2022, the company operated 60 hospitals; and approximately 550 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and other care sites and clinics. Tenet Healthcare Corporation was incorporated in 1975 and is headquartered in Dallas, Texas.
Full company profile →Short Interest
3.5%
2.2 days to cover
OrbiMed Advisors THC Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -465,000 | $0 |
| Q2 2025 | Held | 465,000 | — | $81.8M |
| Q1 2025 | Decreased | 465,000 | -327,000 | $62.5M |
| Q4 2024 | Increased | 792,000 | +10,000 | $100.0M |
| Q3 2024 | Decreased | 782,000 | -391,300 | $130.0M |
| Q2 2024 | Held | 1,173,300 | — | $156.1M |
| Q1 2024 | Decreased | 1,173,300 | -51,100 | $123.3M |
| Q4 2023 | Held | 1,224,400 | — | $92.5M |
| Q3 2023 | Increased | 1,224,400 | +263,900 | $80.7M |
| Q2 2023 | Decreased | 960,500 | -259,800 | $78.2M |
| Q1 2023 | New | 1,220,300 | +1,220,300 | $72.5M |
Frequently Asked Questions
Does OrbiMed Advisors own THC?
No. OrbiMed Advisors exited their position in TENET HEALTHCARE CORP (THC) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own THC?
2 specialist biotech hedge funds currently hold THC, including Rock Springs Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy THC?
OrbiMed Advisors's position in THC was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's THC position increasing or decreasing?
OrbiMed Advisors completely exited their THC position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
THCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →